ARENA PHARMACEUTICALS INC's ticker is ARNA and the CUSIP is 040047607. A total of 167 filers reported holding ARENA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 1.05 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $13,721,000 | +2363.4% | 147,637 | +1478.0% | 0.04% | +2100.0% |
| Q3 2021 | $557,000 | -60.9% | 9,356 | -49.6% | 0.00% | -66.7% |
| Q4 2020 | $1,425,000 | -34.7% | 18,546 | -36.4% | 0.01% | -33.3% |
| Q3 2020 | $2,181,000 | -75.0% | 29,156 | -79.0% | 0.01% | -79.5% |
| Q2 2020 | $8,737,000 | -17.5% | 138,792 | -45.0% | 0.04% | -36.2% |
| Q1 2020 | $10,595,000 | -59.2% | 252,272 | -55.8% | 0.07% | -18.8% |
| Q4 2019 | $25,941,000 | +56.1% | 571,141 | +57.3% | 0.08% | +37.1% |
| Q3 2019 | $16,613,000 | +69.3% | 362,975 | +116.9% | 0.06% | +77.1% |
| Q2 2019 | $9,813,000 | +90.0% | 167,365 | +45.3% | 0.04% | +75.0% |
| Q1 2019 | $5,165,000 | +44.0% | 115,207 | +25.0% | 0.02% | +25.0% |
| Q4 2018 | $3,588,000 | +16.3% | 92,131 | +37.5% | 0.02% | +45.5% |
| Q3 2018 | $3,084,000 | -44.0% | 67,012 | -46.9% | 0.01% | -52.2% |
| Q2 2018 | $5,505,000 | -3.6% | 126,256 | -12.7% | 0.02% | -11.5% |
| Q1 2018 | $5,712,000 | – | 144,600 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 252,500 | $11,320,000 | 4.95% |
| Rubric Capital Management LP | 857,103 | $38,424,000 | 3.59% |
| PFM Health Sciences, LP | 3,255,230 | $145,932,000 | 3.22% |
| Partner Investment Management, L.P. | 40,605 | $1,820,000 | 2.10% |
| DAFNA Capital Management LLC | 93,942 | $4,211,000 | 1.82% |
| Atika Capital Management LLC | 195,000 | $8,742,000 | 1.78% |
| Perceptive Advisors | 1,400,171 | $62,770,000 | 1.77% |
| EMORY UNIVERSITY | 47,779 | $2,142,000 | 1.51% |
| Rhenman & Partners Asset Management AB | 234,558 | $10,515,000 | 1.23% |
| Eversept Partners, LP | 75,721 | $3,394,572 | 0.99% |